A new four-in-one flu vaccine from AstraZeneca has been recommended for approval in Europe, boosting commercial prospects for the next-generation product. Following Friday’s green light from the European Medicines Agency, AstraZeneca said it aimed to replace its current three-strain Fluenz vaccine with quadrivalent Fluenz Tetra from the 2014/15 flu season - assuming the agency’s opinion is endorsed by the European Commission. Unlike traditional injections, AstraZeneca’s vaccine is sprayed into the nose.
Help employers find you! Check out all the jobs and post your resume.
